Business Context and Reporting Period
This Form 8-K Current Report was filed by TopSpin Medical, Inc. on May 11, 2009, covering events occurring on May 5, 2009. The registrant is a Delaware corporation headquartered in Tel Aviv, Israel. The filing discloses the entry into a material definitive consulting agreement with an entity controlled by the Chairman of the Board and significant changes in executive management, specifically the departure of the Director of Finance and the appointment of a new Chief Financial Officer.
Key Financial Metrics and Compensation
The filing does not provide consolidated revenue, profit, cash flow, or debt metrics. Financial data is limited to specific compensation arrangements:
- Chairman Consulting Fee: Mr. Ehud Gilboa (Chairman) will receive a monthly fee of 34,105 NIS (approximately $8,300) for at least 80 hours of service per month, retroactive to January 1, 2009.
- Chairman Expense Reimbursement: The Company will cover up to 50% of fixed and variable maintenance costs for Mr. Gilboa's cellular phone.
- New CFO Salary: Mr. Eldad Yehieli will receive a monthly salary of 25,000 NIS (approximately $6,100).
- New CFO Equity Grant: Mr. Yehieli was granted 1,500,000 stock options (750,000 at ~$0.003/share and 750,000 at ~$0.005/share).
- Outgoing CFO Compensation: Ms. Tami Sharbit-Bachar is entitled to salary payments through June 7, 2009, despite employment terminating May 31, 2009.
Material Changes Versus Prior Period
The filing details the following material changes in corporate governance and personnel:
- Related Party Transaction: Execution of a consulting agreement with Top-Notch Consultancy 2009 Ltd., controlled by Chairman Ehud Gilboa, formalizing services previously discussed in an April 19, 2009 agreement.
- Executive Departure: Tami Sharbit-Bachar, Director of Finance, resigned effective May 31, 2009. Her vested but unexercised options were extended to May 31, 2011, deviating from the standard expiration upon termination.
- Executive Appointment: Eldad Yehieli was appointed Chief Financial Officer effective May 6, 2009, replacing the departing Director of Finance.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding business strategy. Key risks and contingencies identified include:
- Related Party Risk: The consulting agreement involves a controlling shareholder of the Chairman, requiring adherence to Israeli law and specific termination clauses.
- Termination Clauses: Both the Chairman's consulting agreement and the new CFO's employment agreement allow for termination by either party with 45 days' written notice. The Company retains the right to terminate the CFO immediately upon payment of the monthly salary in cases of breach.
- Confidentiality and Non-Compete: The Chairman's agreement includes customary non-compete and confidentiality obligations.
Investor Verification Checklist
- Verify the total retroactive liability for the Chairman's consulting fees from January 1, 2009, to the filing date.
- Confirm the impact of the 1,500,000 new stock options granted to the CFO on existing shareholder dilution.
- Review the full text of Exhibits 10.1 and 10.2 for specific non-compete restrictions and termination conditions.
- Assess the financial impact of the outgoing CFO's salary extension through June 7, 2009.
- Monitor the transition of financial reporting responsibilities following the departure of the Director of Finance.